Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Mar 25, 2004
app pub date -
Mar 26, 2002
filing date -
Apr 26, 2001
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
An improved method for ex-vivo generation of tumor-reactive T cells is provided, comprising culturing PBMC from a patient with cancer with autologous tumor cells and magnetic beads which activate T lymphocytes via CD3 in combination with CD28, CD40, or CD28 plus CD40. The invention also provides genes encoding anti-CD3 or anti-4-1BB scFv and methods to transfect cells of neoplastic or normal origin for expression of those genes at their surface. The genes and transfected tumor cells are useful compositions for induction of a tumor-destructive immune response.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully